What Changed in the 2026 GCP? Understanding the Digital Thread Behind the Regulatory Upgrade

On June 8, 2026, the 2026 revised GCP was jointly issued by four ministries and commissions, taking effect on September 1 and marking the full alignment of China's clinical trial regulation with ICH E6(R3).
To this end, we have compiled the core changes between the 2026 GCP and the 2020 GCP, providing a comparative interpretation alongside ICH E6(R3). Focusing on regulatory upgrades in areas such as data governance, computerized systems, and quality management, we explore the signals the revised GCP sends for digital infrastructure in clinical research.
I. Structural and Terminology Changes: An Upgraded Philosophy
2020 GCP
Comprises nine chapters and 83 articles.
2026 GCP
Streamlined to six chapters and 54 articles; adds a dedicated Chapter 5 on "Data Governance," reflecting the important role of data in clinical trials.
Also noteworthy is the change in core terminology: what was termed "trial participant" in the 2020 edition is renamed "trial participant" in the 2026 edition, referring to an individual participating in a drug clinical trial; it emphasizes that the rights and safety of trial participants are the primary consideration, taking precedence over benefits to science and society.
I. Structural and Terminology Changes: An Upgraded Philosophy
2020 GCP
Comprises nine chapters and 83 articles.
2026 GCP
Streamlined to six chapters and 54 articles; adds a dedicated Chapter 5 on "Data Governance," reflecting the important role of data in clinical trials.
Also noteworthy is the change in core terminology: what was termed "trial participant" in the 2020 edition is renamed "trial participant" in the 2026 edition, referring to an individual participating in a drug clinical trial; it emphasizes that the rights and safety of trial participants are the primary consideration, taking precedence over benefits to science and society.
Key Takeaways
While the document evolves, GCP's original purpose of protecting the rights and interests of trial participants and ensuring data reliability remains unchanged.
II. QbD Formally Enters the Mainstream of GCP
2020 GCP
Introduced risk management concepts, but did not explicitly specify the QbD (Quality by Design) approach.
2026 GCP
This revision explicitly states that quality management should span the entire lifecycle of a drug clinical trial.
Three core principles of ICH E6(R3)—QbD, risk proportionality, and fit for purpose—are incorporated into this GCP revision, with principled requirements established for applying them across all stages of a drug clinical trial.
At the same time, data reliability is standardized around ALCOA+: attributable, legible, contemporaneous, original, accurate, and complete.
This also means that in the future, data compliant with the revised GCP may be more readily accepted by the FDA and EMA, facilitating the global expansion of innovative drugs.
Key Takeaways
Quality management is shifting from the traditional retrospective monitoring model to a proactive, systematic risk management system. When selecting digital systems, pharmaceutical companies need to focus on capabilities for risk identification, early warning, key quality indicator management, and cross-system data insights.
III. Standalone Chapter on Data Governance and Compliance Upgrades
2020 GCP
Data requirements were scattered across different chapters.
2026 GCP
Establishing data governance as a standalone chapter is the clearest reflection of alignment with ICH E6(R3).
Key highlights include:
✔ Data governance across the full lifecycle: Establishes an end-to-end data governance system spanning data capture, transmission, review, analysis, and archiving.
✔ Metadata brought within regulatory scope: Requires all data to be accompanied by metadata and an audit trail, ensuring that data sources are traceable, modifications are recorded, and accountability is maintained.
✔ Computerized systems as an essential safeguard for data trustworthiness: Strengthens requirements for system validation, access control, data backup, information security, and electronic signature management to ensure data integrity and reliability throughout the entire trial.
✔ Blinding management integrated into the data integrity framework: Focuses not only on whether blinding is maintained, but also on assessing the impact of unblinding and accidental unblinding on the credibility of trial results.
Key Takeaways
Future regulatory scrutiny will cover not only data outputs, but the entire process by which data are generated; data are no longer merely an output of clinical trials, but are becoming a core asset across the entire R&D lifecycle. Companies need to establish a governance system covering the full data lifecycle, transitioning from "data management" to "data governance" to ensure traceability and accountability throughout data generation.
IV. Digital Systems Shift from Support Tools to Compliance Infrastructure
2020 GCP
Partially mentioned the application of electronic data and computerized systems.
2026 GCP
Further clarifies system requirements and management responsibilities: Systems and processes used for data capture, management, and analysis should be fit for their intended purpose and proportionate to the risks to trial participants and the importance of the data collected.
Includes:
Computerized system validation
User access management
Audit trail
Data security and backup
Contingency recovery mechanisms
Requirements for inter-system data transfer, etc.
Key Takeaways
Under the requirements of the revised GCP, standalone point tools will find it increasingly difficult to meet regulatory requirements, and an integrated platform with data interoperability will become an important capability.
5. Leaving regulatory room for the application of new technologies
2020 GCP
New technologies are not mentioned.
2026 GCP
Although the 2026 GCP does not directly mention AI, its General Principles state that the application of new technologies and new methods in drug clinical trials should meet ethical, scientific, and relevant legal and regulatory requirements.
This wording reflects a supportive and open regulatory stance toward applying innovative technologies. In particular, the newly added "Data Governance" chapter establishes a foundation for the compliant application of AI and other new technologies in clinical research.
Key takeaway
The compliant application of AI and other new technologies depends on foundational capabilities in data governance, system validation, and data security, rather than on functional innovation alone.
EClinCloud: Continuously building a digital foundation aligned with GCP and regulatory requirements
Under the revised GCP, digital and data-driven capabilities are becoming foundational capabilities for clinical research.
Leveraging its integrated clinical evidence cloud platform, EClinCloud continues to advance innovative practices across areas such as EDC, eCOA, CTMS, eTMF, RTSM, and IRC. Through platform integration and data interoperability capabilities, together with AI- and BI-integrated risk monitoring and data insight capabilities, it helps pharmaceutical companies build a trustworthy data system covering the entire clinical trial lifecycle to better address the regulatory requirements and industry changes brought by the revised GCP.

